Long duration response to levodopa in advanced Parkinson disease
Objective: In patients with advanced Parkinson disease, it is possible to obtain a response to duodopa, if the dose is adjusted appropriately, even taking periods…The neuroprotective properties of NLX-112 in MPTP treated mice are mediated by reactive gliosis and astrocytic GDNF
Objective: To investigate whether NLX-112, a potent and selective 5-HT1A agonist is neuroprotective in a mouse MPTP model of Parkinson’s Disease (PD) [1]. Background: There…Levodopa Carbidopa Intestinal Gel for Parkinson’s Disease over 11 years: A Single Center “Real-World” Experience
Objective: To review long-term real-world experience and clinical outcomes in PD patients with LCIG therapy over 11 years in a multidisciplinary University clinic setting. Background:…Therapeutic potential of luteolin in manganese induced Parkinson’s disease: Targeting neuroinflammation and oxidative stress.
Objective: To investigate the neurodegenerative facets of Manganese (Mn) in rat model in rat model of Parkinson's disease.To study the neuroprotective effect of luteolin in…Long non-coding RNAs in Parkinson’s disease: bringing back life to the grey matter?
Objective: Our study aims to discover and delineate the role of novel long non-coding RNAs (lncRNAs) in Parkinson’s disease (PD). Background: LncRNAs have been widely…Dynamic functional connectivity changes and striatal dopamine deficiency in Parkinson’s disease
Objective: Using a multimodal neuroimaging approach, we assessed whether striatal dopamine synthesis capacity modulates the temporal dynamics of FC in PD. Background: The novel approach…Dopaminergic modulation of express reaching responses in Parkinson’s disease
Objective: This study investigates the role of dopamine (DA) in modulation of automatic stimulus-driven responses. We investigated the effect of PD, DA medication, and instruction…Impact of the dopamine system on long-term, incident cognitive impairment in Parkinson disease
Objective: To determine the impact of the dopamine system (dopamine transporter [DAT] availability, dopamine-related SNPs, and dopaminergic medication use) on long-term cognitive performance in early…Changes in the level of glial neurotrophic factor in Parkinson’s disease depending on the form
Objective: To study the level of glial neurotrophic disease in blood plasma in patients with Parkinson's disease (PD) depending on the form Background: Neurotrophic factors…The study of genetic factors in motor levodopa-induced complications development in Russian patients with Parkinson’s disease
Objective: This study is aimed to explore the relationship between the single nucleotide polymorphisms (SNPs) in dopamine metabolism genes and development of motor side effects…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 26
- Next Page »